OBJECTIVE: To investigate the clinical features and prognosis of patients with methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) community-acquired pneumonia (CAP) producing the Panton-Valentine leukocidin (PVL). METHODS: PubMed and Scopus were searched. Inclusion was stratified according to S. aureus susceptibility and clinical, microbiological and outcome data of patients with S. aureus CAP; both primary and secondary cases of CAP (hematogenous spread from other sites of infection) were included. RESULTS: We identified 71 articles reporting data on patients with MRSA (n = 76) and MSSA (n = 31) PVL-positive CAP. There were no differences in demographics and history among patients with MRSA and MSSA CAP. Features associated with MRSA CAP were gastrointestinal tract symptoms (P = 0.016) and unilobar infiltrates (P = 0.043). Features associated with MSSA CAP were airway hemorrhage (P = 0.01), multilobar infiltrates (P = 0.043) and acute respiratory distress syndrome (ARDS, P = 0.023). Although MSSA patients were more likely to receive initial appropriate antimicrobial therapy (P < 0.001), there was no difference in mortality between the two groups (P = 0.919). Univariate analysis showed that influenza-like symptoms (P < 0.001), multi-organ failure (P < 0.001), admission to the intensive care unit (P < 0.001), mechanical ventilation (P < 0.001), leucopenia (P < 0.001), shock (P = 0.001), development of complications (P = 0.003), vein thrombosis (P < 0.001), disseminated intravascular coagulation (P = 0.03), acidosis (P = 0.012), rash (P = 0.024), ARDS (P = 0.021), necrotizing pneumonia (P = 0.026), and use of macrolides after culture results (P = 0.011) were factors associated with death. CONCLUSIONS: Patients with MRSA PVL-positive CAP did not have higher rates of mortality than patients with MSSA PVL-positive CAP.
OBJECTIVE: To investigate the clinical features and prognosis of patients with methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) community-acquired pneumonia (CAP) producing the Panton-Valentine leukocidin (PVL). METHODS: PubMed and Scopus were searched. Inclusion was stratified according to S. aureus susceptibility and clinical, microbiological and outcome data of patients with S. aureus CAP; both primary and secondary cases of CAP (hematogenous spread from other sites of infection) were included. RESULTS: We identified 71 articles reporting data on patients with MRSA (n = 76) and MSSA (n = 31) PVL-positive CAP. There were no differences in demographics and history among patients with MRSA and MSSA CAP. Features associated with MRSA CAP were gastrointestinal tract symptoms (P = 0.016) and unilobar infiltrates (P = 0.043). Features associated with MSSA CAP were airway hemorrhage (P = 0.01), multilobar infiltrates (P = 0.043) and acute respiratory distress syndrome (ARDS, P = 0.023). Although MSSA patients were more likely to receive initial appropriate antimicrobial therapy (P < 0.001), there was no difference in mortality between the two groups (P = 0.919). Univariate analysis showed that influenza-like symptoms (P < 0.001), multi-organ failure (P < 0.001), admission to the intensive care unit (P < 0.001), mechanical ventilation (P < 0.001), leucopenia (P < 0.001), shock (P = 0.001), development of complications (P = 0.003), vein thrombosis (P < 0.001), disseminated intravascular coagulation (P = 0.03), acidosis (P = 0.012), rash (P = 0.024), ARDS (P = 0.021), necrotizing pneumonia (P = 0.026), and use of macrolides after culture results (P = 0.011) were factors associated with death. CONCLUSIONS:Patients with MRSA PVL-positive CAP did not have higher rates of mortality than patients with MSSA PVL-positive CAP.
Authors: Nadia Z Haque; Samia Arshad; Paula Peyrani; Kimbal D Ford; Mary B Perri; Gordon Jacobsen; Katherine Reyes; Ernesto G Scerpella; Julio A Ramirez; Marcus J Zervos Journal: J Clin Microbiol Date: 2012-02-15 Impact factor: 5.948
Authors: Anupa Kudva; Erich V Scheller; Keven M Robinson; Chris R Crowe; Sun Mi Choi; Samantha R Slight; Shabaana A Khader; Patricia J Dubin; Richard I Enelow; Jay K Kolls; John F Alcorn Journal: J Immunol Date: 2010-12-22 Impact factor: 5.422
Authors: Keven M Robinson; Kevin J McHugh; Sivanarayana Mandalapu; Michelle E Clay; Benjamin Lee; Erich V Scheller; Richard I Enelow; Yvonne R Chan; Jay K Kolls; John F Alcorn Journal: J Infect Dis Date: 2013-09-26 Impact factor: 5.226
Authors: Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: K Z Vardakas; I Kontopidis; I D Gkegkes; P I Rafailidis; M E Falagas Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-20 Impact factor: 3.267
Authors: Zechariah Franks; Robert A Campbell; Adriana Vieira de Abreu; Jeffrey T Holloway; James E Marvin; Bjoern F Kraemer; Guy A Zimmerman; Andrew S Weyrich; Matthew T Rondina Journal: Thromb Haemost Date: 2013-01-24 Impact factor: 5.249
Authors: Keven M Robinson; Sun Mi Choi; Kevin J McHugh; Sivanarayana Mandalapu; Richard I Enelow; Jay K Kolls; John F Alcorn Journal: J Immunol Date: 2013-10-02 Impact factor: 5.422
Authors: Justine K Rudkin; Andrew M Edwards; Maria G Bowden; Eric L Brown; Clarissa Pozzi; Elaine M Waters; Weng C Chan; Paul Williams; James P O'Gara; Ruth C Massey Journal: J Infect Dis Date: 2012-02-01 Impact factor: 5.226